| Literature DB >> 36267489 |
Kulkarni Manik Rao1, N Pooja1.
Abstract
To assess the common presentation and extent of disease involvement clinically and radiologically and treatment modalities, sequalae of the disease, complications and treatment response. Mucormycosis is a life-threatening infection that most commonly affects immunocompromised individuals and an exponential increase in the incidence of Rhino-orbital-cerebral mucormycosis was witnessed in the second wave of the COVID-19 pandemic, despite aggressive multimodal treatment carries a significant risk of mortality. A high index of suspicion is required in order to begin the appropriate diagnostic workup and treatment. This study is conducted to access the outcome and management of mucormycosis in post covid 19 patients. The prospective study includes 180 Patients, who are attending to E.N.T. outpatient department, Triage and patients referred from other departments who had suspected/confirmed Rhino-orbital-cerebral mucormycosis/underwent surgery and/or medical treatment or both. In our study mucormycosis predominantly affected age group between 40 and 60 years, more common in males (77.8%) than females (22.2%), 77.8% patients had post covid status. Most common risk factor was diabetes mellitus.76% patients had undergone endoscopic/open surgery and 24% patients underwent only medical treatment. Among 138 patients operated, 40% had recurrence and mortality was 16.1% (significantly reduced). Early diagnosis and prompt intervention is paramount to reduce morbidity and mortality. Liposomal Amphotericin B is most effective antifungal with manageable side effects. Patients who underwent Radical debridement either endoscopically or open approach, had better outcome with minimal recurrence rates. Combined medical and surgical treatment has better outcome, lesser recurrence and mortality. © Association of Otolaryngologists of India 2022, Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.Entities:
Keywords: FESS (Functional endoscopic sinus surgery); Liposomal Amphotericin B; Mucormycosis; ROCM (Rhino-orbital-cerebral mucormycosis)
Year: 2022 PMID: 36267489 PMCID: PMC9569005 DOI: 10.1007/s12070-022-03197-9
Source DB: PubMed Journal: Indian J Otolaryngol Head Neck Surg ISSN: 2231-3796
Fig. 1Protocol
Demographic distribuitions
| Sl. No. | Frequency | Percent | ||
|---|---|---|---|---|
| 1 | Age | Range 3–82 years | Most prevalent in 40–60 years | |
| 2 | Sex | Female | 40 | 22.2 |
| Male | 140 | 77.8 | ||
| 3 | Post COVID status | Abesnt | 40 | 22.2 |
| Present | 140 | 77.8 | ||
| 4 | KOH | Abesnt | 44 | 24.4 |
| Present | 136 | 75.6 | ||
| 5 | DM | Present | 180 | 100 |
| 6 | DKA | Present | 113 | 62.8 |
| 7 | Electrolyte imbalance | Present | 130 | 72.2 |
| 8 | HT | Present | 128 | 71.1 |
| 9 | Smoker | Present | 130 | 72.2 |
| 10 | Alcoholic | Present | 49 | 27.2 |
| 11 | Anaemia | Present | 4 | 2.2 |
Fig. 2Clinical features in our study population
Adverse reactions to Amphotericin-B
| Sl.no | Reactions | Percentage (%) |
|---|---|---|
| 1 | Fever | 83 |
| 2 | Chills and rigor | 88 |
| 3 | Nausea and vomiting | 70 |
| 4 | Breathlessness | 30 |
| 5 | Chest pain | 20 |
| 6 | Electrolyte imbalance | 72.2 |
| 7 | Anaemia | 50 |
| 8 | Thrombophlebitis | 78 |
Fig. 3Surgical management protocal
Surgical management
| Sl. No | Procedure | Frequency | Percentage |
|---|---|---|---|
| 1 | FESS with debridement | 138 | 76 |
| 2 | Medial maxillectomy | 41 | 30 |
| 3 | Modified Denker’s/Caldwell Luc | 39 | 21.7 |
| 4 | Orbital decompression | 125 | 69.4 |
| 5 | Clival/Retro sphenoid clival and other skull base approach | 2 | 1.3 |
| 6 | Infratemporal fossa/Pterygopalatine fossa | 60 | 33.3 |
| 7 | Infrastructure maxillectomy | 41 | 30 |
| 8 | TOTAL maxillectomy | 21 | 15 |
| 9 | Extended maxillectomy | 10 | 7.24 |
| 10 | Orbital Exenteration | 10 | 7.25 |
| Sl. No. | Frequency | Percentage | ||
|---|---|---|---|---|
| 1 | Follow up at 1 month | No recurrence | 0 | 0 |
| 2 | Follow up at 3 months | Recurrence | 55 | 40 |
| 3 | Follow up at 6 months | No recurrence | 0 | 0 |
| Recurrence treatment | infrastructure maxillectomy/Palatectomy | 15 | 10.86 | |
| Orbital Exenteration | 17 | 12.31 | ||
| Total/extended maxillectomy | 11 | 8 | ||
| Infratemporal fossa/Pterygopalatine fossa | 12 | 8.69 | ||
| 4 | Outcome | Death | 29 | 16.1 |
| Good | 151 | 83.9 |